Search

Background: We retrospectively investigated the role of (neo)adjuvant chemotherapy in patients with primary, localized angiosarcoma., Methods: We selected all patients with primary, localized angiosarcoma, who had received radical surgery between January 2005 and December 2019 at 33 European sarcoma reference centers. The primary objective was to compare the outcome of patients who received (neo)adjuvant chemotherapy versus those who did not, in terms of overall survival (OS), disease-free survival (DFS) and distant metastasis-free survival (DMFS). To reduce the risk of confounding due to imbalance, a propensity-score matching(PSM) was performed. Finally, subgroups analysis was performed according to tumor site, tumor size (< 50 mm or ≥ 50 mm) and patients predicted 10-years OS according to the nomogram sarculator (two different cutoff-values were applied: ≤ 33% or > 33% and < 60% or ≥ 60%)., Results: 362 patients were analyzed: 149 (41.2%; treated group) received (neo) adjuvant chemotherapy and 213 (58.6%; control group) did not. The median follow-up for the OS endpoint was 5.1 years (95% CI: 4.0-5.5). The OS-HR was 0.58 (95%CI: 0.40-0.83; p-value = 0.003) in the univariate analysis and 0.74 (95% CI: 0.38-1.43; p = 0.367) in the PSM analysis. The DFS-HR was 0.75 (95% CI: 0.57-0.98; p-value = 0.036) in the univariate analysis, and 0.91 (95% CI:0.56-1.48; p-value = 0.7) in the PSM analysis. The DMFS-HR was 0.75 (95% CI: 0.55-1.02; p-value = 0.065) in univariate analysis and 0.92 (95% CI: 0.53-1.61; p-value = 0.769) in the PSM analysis. Subgroup analysis revealed no heterogeneity of results in strata of tumor site. On the contrary, there was a trend for heterogeneity according to tumor size and patient's risk of death. For all the endpoints analyzed, patients with tumors smaller than 50 mm or at lower risk of death seem to have no benefit from chemotherapy, while patients with larger tumors or at higher risk of death at 10 years seem to derive substantial benefit., Conclusion: This large, retrospective study suggests that patients affected by > 50 mm and/or high-risk primary, localized angiosarcoma could benefit from (neo)adjuvant chemotherapy., Competing Interests: Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article., (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Rice is a crop that presents sensitivity to cold, especially in the germination phase, which leads to high economic losses. Alternative management forms are essential to increase tolerance to low temperatures, and seed priming represents a promising tool. The objective of this study was to investigate the priming effect of the aqueous extract of carrot roots on rice seeds to increase tolerance to low temperatures during germination. Seeds from cultivars BRS Querência (cold-susceptible) and Brilhante (cold-tolerant) were soaked for 24 h in concentrations of 0, 25, 50, and 100% carrot extract, sown on germitest paper and conditioned in BOD for 21 days at 15 °C. As a control, the seeds soaked in water were also germinated at 25 °C. They were evaluated for germination, first germination count, and germination speed index to calculate the stress indices: tolerance index, susceptibility index, and harmonic mean. They were also evaluated for the length and dry mass of shoot and root. The results showed that the rice seeds conditioning in carrot extract effectively reduces the damage caused by cold, significantly increasing the germination speed and the percentage of final germination and the growth evaluations, more expressive at 100% concentration. The stress indexes are efficient in estimating the tolerance of the cultivars and the effect of the different conditions in low-temperature conditions, highlighting the superiority of the Brilhante cultivar.